LIMD2: A Protein Targeted for Drug Treatment (G80774)

Target Name: LIMD2

NCBI ID: G80774

LIMD2

Other Name(s): LIMD2_HUMAN | LIM domain-containing protein 2 | LIM domain containing 2 | MGC10986 | testicular tissue protein Li 106

LIMD2: A Protein Targeted for Drug Treatment

LIMD2 (LIMD2-HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, heart, and liver. It is a key regulator of cell division and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and developmental disorders.

One of the unique features of LIMD2 is its ability to interact with other proteins, known as LIM domain proteins, which are found in many different cell types. This interaction allows LIMD2 to regulate the activity of these other proteins and to play a role in a wide range of physiological processes, including cell growth, differentiation, and disease.

One of the most promising aspects of LIMD2 is its potential as a drug target. By interacting with LIM domain proteins, LIMD2 has been shown to play a role in a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders. This suggests that targeting LIMD2 with drugs or other therapeutic agents may be a promising strategy for treating these conditions.

One of the key challenges in targeting LIMD2 is its widespread distribution in the body. While LIMD2 is expressed in many different tissues of the human body, it is not widely targeted by the immune system, which can make it difficult to deliver drugs or other therapeutic agents to the affected cells.

Another challenge is the complexity of the LIMD2 signaling pathway. While LIMD2 has been shown to play a role in a wide range of physiological processes, it is not clear exactly how it interacts with the other proteins in the pathway. This lack of understanding can make it difficult to design effective drugs or other therapeutic agents that target LIMD2.

Despite these challenges, there is growing interest in targeting LIMD2 as a potential drug or biomarker. Researchers are working to develop small molecules and other compounds that can interact with LIMD2 and to determine their effectiveness in treating a variety of diseases.

One approach to targeting LIMD2 is to use small molecules that can inhibit its activity as a regulator of cell division. This approach is based on the idea that by disrupting LIMD2's ability to regulate cell growth, researchers can treat diseases that are caused by out-of-control cell division.

Another approach to targeting LIMD2 is to use antibodies that can specifically recognize and target the protein. This approach is based on the idea that by using antibodies to deliver small molecules or other therapeutic agents directly to the affected cells, researchers can treat diseases caused by LIMD2's activity.

While there is still much to be learned about the biology and pharmacology of LIMD2, its potential as a drug target is an exciting area of research. By targeting LIMD2 with small molecules or antibodies, researchers may be able to treat a wide range of diseases and improve the quality of life for many people.

Protein Name: LIM Domain Containing 2

Functions: Acts as an activator of the protein-kinase ILK, thereby regulating cell motility (PubMed:24590809)

The "LIMD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LIMD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets